Список литературы

1.

2. Адаскевич В. П. Диагностические индексы в дерматологии//М.,-2004.-160c.

3. Баткаев Э.А., Галямова Ю.А. Склеродермия // Учебное пособие. Российская медицинская академия последипломного образования.

4. Белоусова Т. А., Колмогорова И. В., Мокина Е. В. Гемиатрофия лица Ромбер- га: современный взгляд на проблему // Российский журнал кожных и вене- рических болезней - 1999. - № 5. - С. 20–23.

5. Белоусова Т.А., Теплюк Н.П., Кладова АЛО. О нозологической принадлеж- ности атрофодермии Пазини Пьерини // Клиническая дерматология и вене- рология. - 2003. - № 2. - С. 16-19.

6. Болотная Л. А., Шахова Ф. Б., Сербина И. М. Новое в патогенезе и терапии ограниченной склеродермии // Вестник дерматогии и венерологии - 2004. -

№ 2. - С. 31–34.

7. Бутов Ю.С. // Антинуклеарные антитела у больных системными заболевани- ями // Вестн. дерматол. – 1980. – II. – C. 17–21.

8. Владимирцев В.А., Авдеева Ж.И., Гусева Н.Г. и др. // Изучение клеточного иммунного ответа на коллаген I типа у больных системной склеродермией.

– Вопр. ревмат. – 1982. – I. – С. 33–38.

9. Волнухин В.А. Некоторые вопросы терминологии и классификации склеро- дермии // Рос. журн. кожн. и вен. бол. 2002. - № 4. - С. 30-33.

10. Выборнова О.В., Волнухин В.А., Вавилов A.M. и соавт. Гистологическое, гистохимическое, электронно-микроскопическое и электронно-цитохими- ческое исследование кожи больных ограниченной склеродермией // Рос. журн. кожн. и вен. бол. 2002. - № 4. - С. 33-37.

11. Гончарова Л.И., Харитонова Н.И. Сочетание идиопатической атрофодермии Пазини-Пьерини и бляшечной склеродермии // Вестн. дерматол. венерол. 1988. - № 7. - С. 68-69.

12. Гусева Н.Г. Проблемы диагностики и лечения системной склеродермии //

Рус. мед. журн. 1998. - Т. 6. - № 8. - С. 486-492.

12 .Гусева Н.Г. Системная склеродермия и псевдосклеродермические синдромы //М., Медицина.- 1993.

13 .Довжанский С. И. Клинико-иммунологические параллели при ограниченной и системной склеродермии // Рос. журн. кожн. и вен. бол. 2002, № 4. С. 26– 29.

14 .Долбин А.Г., Федорова Е.Г., Зарецкая Ю.М. Антигены системы HLA у боль- ных очаговой склеродермией и атрофодермией Пазини-Пьерини // Вестн. дерматол. венерол. 1978. - № 7. - С. 16-19

15 .Иванова С.М. Клинико-иммунологические особенности диффузных болез- ней соединительной ткани с антителами,к экстрагируемым ядерным-анти- генам.//Диссертация на соискание ученой степени кандидата медицинских наук. Москва.- 1984.- C. 130.

16 .Иванова С.М., Гусева Н.Г., Зацепина О.В. и соавт. Аутоиммунитет при скле- родермии // Сборник трудов. Современные проблемы аллергологии, клини- ческой иммунологии и иммунофармакологии. М., 1998. - С. 365.

17 .Мордовцев В.Н., Прохоров А.Ю. Мордовцев В.Н. и др. Современные концеп- ции по патогенезу псориаза // Вестник дерматологии - 1987. - № 7. - C.28-33.

18 .Новак А. А., Ионова Т. И. Руководство по исследованию качества жизни в медицине. – СПб.,-2002.-320с.

19. Пальцев М.А. Клинико-морфологическая диагностика заболеваний кожи /

Пальцев М. А., Потекаев Н. Н. - М.: Медицина, 2004. - С.

20.Пирузян Э.С., Ишкин А.А., Никольская Т.А. и др. Сравнительный анализ мо- лекулярно-генетических процессов при патогенезе псориаза и болезни Крона // Молекулярная биология - 2009. - Т. 43, № 1 - С. 175-179.

21. Пирузян Э.С., Никольская Т.А., Абдеев Р.М., Брускин С.А. Компоненты транскрипционного фактора AP-1 как гены-кандидаты, участвующие в развитии псориатического процесса // Молекулярная биология. - 2007. - Т.41

- С. 1069-1080.

22 .Потекаев Н.  С., Потекаев Н. Н. Болезнь Лайма и обусловленные ею поражения кожи // Вестник дерматологии и венерологии - 2006. - № 6. - С. 3– 9

23 .Разумов А.Н., Покровский В.И. Здоровье здорового человека.-М.,-2007.-С.

15-24.

24 .Соболев В.В., Стародубцева Н.Л., А.Л. Пирузян, и др. Сравнительное исследование экспре ссии генов ATF-3 и ATF-4 в пораженных атеросклеротическим процессом сосудах и в коже при псориатическом процессе // Бюллетень экспериментальной биологии и медицины - 2011.

25 .Турпаев К.Т. Роль фактора т ранскрипции AP-1 в интеграции внутриклеточных сигнальных систем // Молекулярная биология - 2006. - Т. 40, № 6. - С. 945-961

26 .Хамаганова И.В., Савина М.И., Свешникова Е.Е. Характеристика ядерных компонентов лимфоцитов при очаговой склеродермии // Рос. журн. кожн. и вен. бол. - 2002. - № 4. - С. 42-44.

27. Antic M, Lautenschlager S, Itin PH. Eosinophilic fasciitis 30 years after—what do we really know? Report of 11 patients and review of the literature // Dermatology

- 2006. - Vol.213, N 2. - Pp. 93–101.

28. Arkachaisri T, Vilaiyuk S, Li S, O’Neil KM, Pope E, Higgins GC, et al. The localized scleroderma skin severity index and physician global assessment of disease activity: a work in progress toward development of localized scle- roderma outcome measures // J Rheumatol - 2009. - Vol. 36, N 2. - Pp. 2819-2829.

29. Arkachaisri T, Vilaiyuk S, Torok KS, Medsger TA Jr. Develop- ment and initial validation of the localized scleroderma skin damage index and physician global assessment of disease damage: a proof-of-concept study // Rheumatology (Oxford) - 2010. - Vol. 49, N 2. - Pp. 373-381.

30. Azad J, Dawn G, Shaffrali FCG et al. Does solitary morphoea profundus pro- gress? // Clin Exp Dermatol - 2004. - Vol. 29, N 1. - Pp. 25–27.

31. Bakiri, L., Matsuo, K., Wisniewska, M., Wagner, E.F., and Yaniv, M. Promoter specificity and biological activity of tethered AP-1 dimers // Mol Cell Biol - 2002. - Vol. 22 - Pp. 4952-4964.

32. Barbagli G, Palminteri E, Balo S et al. Lichen sclerosus of the male genitalia and urethral stricture diseases // Urol Int - 2004. - Vol. 73, N 1. - Pp.1–5.

33. Barbarino Julia M, Staatz Christine E, Venkataramanan Raman, Klein Teri E, Altman Russ B. PharmGKB summary: cyclosporine and tacrolimus pathways // Pharmacogenetics and genomics - 2013. - Vol. 23, N 10. - Pp 563-585.

34. Barnes TC, Spiller D, Anderson ME, Edwards SW, Moots RJ. Endothelial cell activation and apoptosis mediated by neutrophil-dependent interleukin 6 trans- signalling: a novel target for systemic sclerosis? // Annals of the Rheumatic Diseases -2011.

35. Birdi N, Laxer RM, Thorner P, Fritzler MJ, Silverman ED: Localized scleroderma progressing to systemic disease. Case report and review of the literature // Arthritis and rheumatism - 1993. -Vol. 36, N 3. - Pp. 410-415.

36. Bohmann, D., Bos, T.J., Admon, A., Nishimura, T., Vogt, P.K., and Tjian, R. Human proto-oncogene c-jun encodes a DNA binding protein with structural and functional properties of transcription factor AP-1 // Science - 1987. - Vol. 238, N 4832. - Pp. 1386-1392.

37. Bramley P, Forbes A. A case of progressive hemiatrophy presenting with spon- taneous fractures of the lower jaw // BMJ - 1960. - Vol. 1, N 584. - Pp. 1476– 1478.

38. Bruckdorfer KR, Hillary JB, Bunce T, Vancheeswaran R, Black CM. Increased susceptibility to oxidation of low-density lipoprotein isolated from patients with systemic sclerosis // Arthritis Rheum - 1995. - Vol. 38, N 8. -Pp. 1060-1067.

39. Buechner SA, Rufli T. Atrophoderma of Pasini and Pierini. Clinical and histopathologic findings and antibodies to Borrelia burgdorferi in thirty-four patients // J Am Acad Dermatol - 1994. - Vol. 30, N 3. - Pp. 441-446.

40. Burgdorf WHC, Worret W, Schultka O. Acrodermatitis chronica atrophicans //Int J Dermatol - 1979. - Vol. 18 - Pp. 595–601

41. Casciola-Rosen L, Wigley F, Rosen A. Scleroderma autoantigens are uniquely fragmented by metal-catalyzed oxidation reactions: Implications for pathogenesis

// J Exp Med - 1997. - Vol. 185, N 1. - Pp. 71-79.

42. Caubet, J.F., Mitjavila, M.T., Dubart, A., Roten, D., Weil, S.C., and Vainchenker,

W. Expression of the c-fos protooncogene by human and murine erythroblasts // Blood - 1989. - Vol. 74, N 3. - Pp. 947-951.

43. Chen, L., Glover, J.N., Hogan, P.G., Rao, A., Harrison, S.C. Structure of the DNA- binding domains from NFAT, Fos and Jun bound specifically to DNA // Nature - 1998. - Vol. 392 - Pp. 42–48.

44. Chinenov, Y., Kerppola, T.K. Close encounters of many kinds: Fos–Jun interactions that mediate transcription regulatory specificity // Oncogene - 2001.

-Vol. 20, N 19. - Pp. 2438–2452.

45. Cho JW, Cha YC, Lee KS: AP-1 transcription factor decoy reduces the TGF- beta1-induced cell growth in scleroderma fibroblasts through inhibition of cyclin E // Oncology reports - 2008. - Vol. 19, N 3. - Pp. 737-741.

46. Cho JW, Kim JY, Kim CW, Lee KS: Down-regulation of TGF-beta1-induced type I collagen synthesis by AP-1 transcription factor decoy in scleroderma fibroblasts

// Journal of dermatological science - 2006 - Vol. 43, N 3. - Pp. 207-209.

47. Choi SW, Yang JE, Park HJ et al. A case of extragenital lichen sclerosus following Blaschko’s lines // J Am Acad Dermatol - 2000. - Vol. 43, N 5. - Pp. 903–904. 48.Christianson HB, Dorsey ES, O’Leary PA, Kierland R. Localized scleroderma: a clinical study of 235 cases // Arch Dermatol - 1956. - Vol. 74 - Pp. 629–639. 49.Chung KY, Agarwal A, Uitto J, Mauviel A. An AP-1 binding sequence is essential

for regulation of the human alpha2(I) collagen (COL1A2) promoter activity by transforming growth factor-beta // The Journal of biological chemistry - 1996. - Vol. 271, N 6. - Pp. 3272-3278.

50. Chung L, Lin J, Furst DE, Fiorentino D. Systemic and localized scleroderma // Clin Dermatol - 2006. - Vol.24, N 5. - Pp. 374-392.

51. Cotton SA, Herrick AL, Jayson MI, Freemont AJ: TGF beta--a role in systemic sclerosis? // The Journal of pathology - 1998. - Vol. 184, N 1. - Pp. 4-6.

52. Cowper SE, Robin HS, Steinberg SM et al. Scleromyxoedema-like cutaneous diseases in renal dialysis patients // Lancet - 2000. - Vol. 356, N 9234. - Pp. 1000–1001.

53. D’Arpa O, White-Cooper H, Cleveland DW, Rothfield NF, Earnshaw WC. Use of molecular cloning methods to map the distribution of epitopes on topoisomerase I (Scl-70) recognized by sera of scleroderma patients // Arthritis Rheum - 1990. - Vol.33, N 10. - Pp. 1501–1511.

54. Daoud MS, Su WPD, Leiferman KM, Perniciaro C. Bullous morphea: clinical, pathologic, and immunopathologic evaluation of 13 cases // J Am Acad Dermatol

- 1994.

55. Denton CP, Abraham DJ: Transforming growth factor-beta and connective tissue growth factor: key cytokines in scleroderma pathogenesis // Current opinion in rheumatology - 2001. - Vol. 13, N 6. - Pp. 505-511.

56. Derynck R, Feng XH. TGF-beta receptor signaling // Biochim Biophys Acta - 1997. - Vol. 1333 - Pp. 105–150.

57. Di Silverio A, Serri F. Generalized bullous and haemorrhagic lichen sclerosus et atrophicus // Br J Dermatol - 1975. - Vol. 93, N 2. - Pp. 15–7.

58. Diaz-Perez JL, Connolly SM, Winkelmann RK. Disabling pansclerotic morphoea

of children // Arch Dermatol - 1980. - Vol. 116, N 2. - Pp. 169–73

59. Dony, C., and Gruss, P. Proto-oncogene c-fos expression in growth regions of fetal bone and mesodermal web tissue // Nature - 1987. - Vol. 328, N 6132. - Pp. 711- 714.

60. Dooley A, Shi-wen X, Aden N, Tranah T, Desai N, Denton CP, et al. Modulation of collagen type I, fibronectin and dermal fibroblast function and activity, in systemic sclerosis by the antioxidant epigallocatechin- 3-gallate //Rheumatology

- 2010. - Vol. 49, N 11. - Pp. 2024-2036.

61. Dytoc MT, Kossintseva I, Ting PT. First case series on the use of calcipotriol- betamethasone dipropionate for morphoea // Br J Dermatol - 2007. - Vol.157, N 3. - Pp. 615-618.

62. Eickelberg O, Pansky A, Koehler E, Bihl M, Tamm M, Hildebrand P, Perruchoud AP, Kashgarian M, Roth M. Molecular mechanisms of TGF-beta antagonism by interferon-γ and cyclosporine A in lung fibroblasts // FASEB J - 2001. - Vol. 15, N 3. - Pp. 797–806.

63. Elovic AE, Ohyama H, Sauty A, McBride J, Tsuji T, Nagai M, et al. IL-4- dependent regulation of TGFalpha and TGFbeta1 expression in human eosinophils // J Immunol - 1998. - Vol. 160, N 12. - Pp.6121-6127.

64. Farrell AM, Marren PM, Wojnarowska F. Genital lichen sclerosus associated with morphoea or systemic sclerosus: clinical and HLA characteristics // Br J Dermatol - 2000. - Vol. 143, N 3. - Pp. 598–603.

65. Ferrari N, Pfeffer U, Dell'Eva R, Ambrosini C, Noonan DM and Albini A The transforming growth factor-beta family members bone morphogenetic protein-2 and macrophage inhibitory cytokine-1 as mediators of the antiangiogenic activity of N-(4- hydroxyphenyl) retinamide // Clin Cancer Res - 2005 - Vol. 11, Pp. 4610-4619.

66. Flanga V, Medsger TA Jr, Reichlin M. Antinuclear and anti-single-stranded DNA antibodies in morphea and generalized morphea // Arch Dermatol - 1987. - Vol. 123, N 3. - Pp. 350–353.

67. Fleischmajer R, Perlish JS, Reeves JR. Cellular infiltrates in scleroderma skin // Arthritis Rheum - 1977. - Vol. 20, N 4. - Pp. 975–84.

68. Flindt-Hansen H, Isager H. Scleroderma after occupational exposure to trichlor- ethylene and trichlorethane // Acta Derm Venereol (Stockh) - 1987. - Vol. 67, N 3. - Pp. 263–264.

69. Galindo M, Santiago B, Alcami J, Riyero M, Martin- Serrano J, Pablos JL. Hypoxia induces expression of the chemokines monocyte chemoattractant protein-1 (MCP-1) and IL-8 in human dermal fibroblasts // Clin Exp Immunol - 2001. - Vol. 123, N 1. - 36-41.

70. Greenberg, M.E., and Ziff, E.B. Stimulation of 3T3 cells induces transcription of the c-fos proto-oncogene // Nature - 1984 - Vol. 311, Pp. 433-438.

71. Grigoriadis, A.E., Schellander, K., Wang, Z.Q., and Wagner, E.F. Osteoblasts are target cells for transformation in c-fos transgenic mice // J Cell Biol - 1993. - Vol. 122, N 3. - Pp. 685-701.

72. Grobner T. Gadolinium—a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? // Nephrol Dial Transplant - 2006. - Vol. 21, N 4. - Pp. 1104–1108.

73. Gupta RA, Fiorentino D. Localized scleroderma and systemic sclerosis: is there a connection? // Best Pract Res Clin Rheumatol - 2007. - Vol. 21, N 6. - Pp. 1025-1036.

74. Halazonetis, T.D., Georgopoulos, K., Greenberg, M.E., and Leder, P. c-Jun dimerizes with itself and with c-Fos, forming complexes of different DNA binding affinities // Cell - 1988. - Vol. 55, N 5. - Pp. 917-924.

75. Harding H, Zhang Y, Zeng H, Novoa I, Lu P, Calfon M, Sadri N, Yun C, Popko B, Paules R, Stojdl D, Bell J, Hettmann T, Leiden J and Ron D. An integrated stress response regulates amino acid metabolism and resistance to oxidative stress // Molecular Cell - 2003. - Vol.11, N 3. - Pp. 619-633.

76. Harding, H. P., I. Novoa, Y. Zhang, H. Zeng, R. Wek, M. Schapira, and D.,Ron.

Regulated translation initiation controls stress-induced gene expression in mammalian cells // Mol. Cell - 2000 Vol. 6, N 5 - Pp. 1099–1108.

77. Hasegawa M, Sato S, Fujimoto M, et al. Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis // J Rheumatol - 1998. - Vol. 25, N 2. - Pp. 308–13.

78. Hayakawa I, Hasegawa M, Takehara K, Sato S. Anti-DNA topoisomerase II

autoantibodies in localized scleroderma //Arthritis Rheum - 2004. - Vol.50, N 1.

- Pp.227–232.

79. Hess EV. Is there a phospholipid specificity of lupus anticoagulants (LAC) in patients with autoimmune and drug induced LAC? // J Rheumatol - 1998. - Vol. 25, N 2. - Pp. 200–202.

80. Hess J., Angel P., Schorpp-Kistner M. AP-1 subunits: quarrel and har- mony among siblings // J Cell Sci - 2004. - Vol. 117, N 25. - Pp. 5965—5973.

81. Higley H, Persichitte K, Chu S, Waegell W, Vancheeswaran R, Black C. Immunocytochemical localization and serologic detection of transforming growth factor beta 1. Association with type I procollagen and inflammatory cell markers in diffuse and limited systemic sclerosis, morphea, and Raynaud's phenomenon //Arthritis Rheum - 1994. - Vol. 37, N 2. - Pp. 278–288

82. Hinnen U, Schmid-Grendelmeier P, Muller E et al. Losungsmittelexposition bei Sklerodermie: disseminierte zirkumskripte Sklerodermie (Morphea) bei einem Perchlorethylen-exponierten Lackierer // Schweiz Med Wochenschr - 1995. - Vol. 125 - Pp. 2433–2437.

83. Hirai, S.I., Ryseck, R.P., Mechta, F., Bravo, R., and Yaniv, M. Characterization of junD: a new member of the jun proto-oncogene family // Embo J - 1989 - Vol. 8, N 5. - Pp. 1433-1439.

84. Horstmeyer A, Licht C, Scherr G, Eckes B, Krieg T. Signaling and regulation of collagen I synthesis by ET-1 and TGFβ1 // FEBS J - 2005. - Vol. 272, N 24. - Pp. 6297-309.

85. Ihn H, Fujimoto M, Sato S, et al. Increased levels of circulating intercellular adhesion molecule-1 in patients with localized scleroderma // J Am Acad Dermatol - 1994. - Vol. 31, N 4. - Pp. 591–595.

86. Ihn H, Yamane K, Kubo M, Tamaki K. Blockade of endogenous transforming growth factor β signaling prevents up-regulated collagen synthesis in scleroderma fibroblasts: association with increased expression of transforming growth factor β receptors // Arthritis Rheum - 2001. - Vol. 44, N 2. - Pp. 474–80.

87. Jablonska S. Scleroderma-like lesions in phenylketonuria / S. Jablonska, A. Stachow // Scleroderma and Pseudoscleroderma - Warsaw: Polish Medical Publishers, 1975 - Pp. 489–98.

88. Jacobson L, Palazij R, Jaworsky C. Superficial morphoea // J Am Acad Dermatol - 2003. - Vol. 49, N 2. - Pp. 323–325.

89. Janovski NA, Ames S. Lichen sclerosus et atrophicus of the vulva // Obstet Gynecol - 1963. - Vol. 22 -Pp. 697–708.

90. Jappe U, Holzle E, Ring J. Parry–Romberg syndrom Zussamenfassung und neue Erkenntnisse anlablich einer ungewhnlichen Kasuistik // Hautarzt - 1996. - Vol. 47, N 8. - Pp. 599–603.

91. Jenkins G. The role of proteases in transforming growth factor-beta activation // Int. J. Biochem. Cell Biol. - Vol. 40, N 6-7. - Pp. 1068-1078.

92. Johansen, C., Kragballe, K., Rasmussen, M., et al. Activator protein 1 DNA binding activity is decreased in lesional psoriatic skin compared with nonlesional psoriatic skin // Br. J. Dermatol. - 2004. - Vol. 151, N 3. - Pp. 600-607.

93. Kaplanski G, Marin V, Montero-Julian F, et al. IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation //Trends Immunol

- 2003. - Vol. 24, N 1. - Pp. 25–29.

94. Karin M, Liu Z, Zandi E. AP-1 function and regulation // Curr Opin Cell Biol. - 1997. - Vol. 9, N 2. - Pp. 240-246.

95. Karin M. The regulation of AP-1 activity by mitogen-activated protein kinases // J Biol Chem. - 1995. - Vol. 270, N 28. - Pp. 16483-6.

96. Kawakami T, Ihn H, Xu W, Smith E, LeRoy EC, Trojanowska M. Increased expression of TGF- β receptors by scleroderma fibro- blasts: evidence for contribution of autocrine TGF-β signaling to scleroderma phenotype // J Invest Dermatol - 1998. - Vol. 110, N 1. - Pp. 47–51.

97. Kencka D, Blaszczyk M, Jablonska S. Atrophoderma Pasini-Pierini is a primary atrophic abortive morphea // Dermatology - 1995. - Vol. 190, N 3. - Pp.203-206.

98. Koch AE, Kronfeld-Harrington LB, Szekanecz Z, et al. In situ expression of cytokines and cellular adhesion molecules in the skin of patients with systemic sclerosis. Their role in early and late disease // Pathobiology - 1993. - Vol. 61, N 5-6. - Pp. - 239–246.

99. Korn J.H., Mayes M., Cerinic M.M. et al. Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist // Arthr Rheum - 2004. -Vol.50, N 2. - Pp. 3985—3993.

100. Kroft EB, Groeneveld TJ, Seyger MM, de Jong EM. Efficacy of topical tacrolimus 0.1% in active plaque morphea: random- ized, double-blind,

emollient-controlled pilot study // Am J Clin Dermatol - 2009. - Vol.10, N 3. - Pp.181-187.

101. Kubo M, Ihn H, Yamane K, Tamaki K. Up-regulated expression of transforming growth factor β receptors in dermal fibroblasts in skin sections from patients with localized scleroderma // Arthritis Rheum - 2001. - Vol. 44, N 3. - Pp. 731–734.

102. Kulski JK, Kenworthy W, Bellgard M, Taplin R, Okamoto K, Oka A, Mabuchi T, Ozawa A, Tamiya G, Inoko H: Gene expression profiling of Japanese psoriatic skin reveals an increased activity in molecular stress and immune response signals // Journal of molecular medicine (Berlin, Germany) - 2005. -Vol. 83, N 12. - Pp. 964-975.

103. Kuwana M., Okazaki Y ., Yasuoka H., Kawakami Y ., Ikeda Y. D e f e c t i v e vasculogenesis in systemic sclerosis // Lancet - 2004. - Vol. 364, N 9434 - Pp. 603-610.

104. Labandiera J, Leon-Mateos A, Suarez-Penaranda JM et al. What is nodular- keloidal scleroderma? // Dermatology - 2003. - Vol. 207, N 2 - Pp. 130–132. 105.Lakhampal S, Ginsberg WW, Michet CJ et al. Eosinophilic fasciitis: clinical

spec- trum and therapeutic response in 52 cases // Semin Arthritis Rheum - 1988. - Vol. 17, N 4. - Pp. 221–231.

106. Larregue M, Ziegler JE, Lauret P et al. Sclerodermie en bande chez l’enfant (a propos de 27 cas) // Ann Dermatol Venereol - 1986. - Vol. 113, N 3. - Pp. 207– 224

107. Laxer RM, Zulian F. Localized scleroderma // Curr Opin Rheumatol. - 2006. - Vol. 18, N 6. - Pp. 606-613.

108. Leask A., Abraham D.J. TGF-β signaling and the fibrotic response // FASEB J. - 2004. - Vol. 18, N 7. - Pp. 816–827.

109. Lebeaux D, Francès C, Barete S, Wechsler B, Dubourg O, Renoux J, et al.

Eosinophilic fasciitis (Shulman disease): new insights into the therapeutic management from a series of 34 patients // Rheumatology (Oxford) - 2012. -Vol. 51, N 3. - 557-561

110. Leitenberger JJ, Cayce RL, Haley RW, Adams-Huet B, Bergstresser PR, Jacobe HT. Distinct autoimmune syndromes in morphea: a review of 245 adult and pediatric cases // Arch Dermatol. - 2009. - Vol. 145, N 5. - Pp. 545-50.

111. Li, B., Tournier, C., Davis, R.J., and Flavell, R.A. Regulation of IL-4 expression by the transcription factor JunB during T helper cell differentiation // Embo J - 1999. - Vol. 18, N 2. - Pp. 420-432.

112. Lim YL, Lee HY, Low SCS et al. Possible role of gadolinium in nephrogenic systemic fibrosis: report of two cases and review of the literature // Clin Exp Dermatol - 2007. - Vol. 32, N 4. - Pp. 353–358.

113. Liska DJ, Slack JL, Bornstein P. A highly conserved intronic sequence is involved in transcriptional regulation of the α1(I) collagen gene // Cell Regul - 1990. - Vol. 1, N 6. - Pp. 487–498.

114. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real- time quantitative PCR and the 2(-Delta Delta C(T)) Method // Methods (San Diego, Calif) - 2001. - Vol. 25, N 4. - Pp. 402-408.

115. Macian, F. NFAT proteins: key regulators of T-cell development and function // Nature Reviews Immunology - 2005. -Vol. 5, N 6. - Pp. 472–484.

116. Macian, F., Garcia-Rodriguez, C., Rao, A. Gene expression elicited by NFAT in the presence or absence of cooperative recruitment of Fos and Jun // EMBO Journal - 2000. - Vol. 19, N 17. - Pp. 4783–4795.

117. Maki, Y., Bos, T.J., Davis, C., Starbuck, M., and Vogt, P.K. Avian sarcoma virus 17 carries the jun oncogene // Proc Natl Acad Sci U S A - 1987. - Vol. 84, N 9. - Pp. 2848-2852.

118. Maragh SH, Davis MDP, Bruce AJ et al. Disabling pansclerotic morphea: clinical presentation in two adults // J Am Acad Dermatol - 2005. - Vol. 53, N 2., Suppl 1. - Pp - 115–119.

119. Markovics JA, Araya J, Cambier S, Somanath S, Gline S, Jablons D, Hill A, Wolters PJ, Nishimura SL. Interleukin-1beta induces increased transcriptional activation of the transforming growth factor-beta-activating integrin subunit

beta8 through altering chromatin architecture // J Biol Chem. - 2011. - Vol. 286, N 42. - Pp. 36864-36874.

120. Massague J. How cells read TGF-beta signals // Nat Rev Mol Cell Biol - 2000. - Vol. 1, N 3. - Pp. 169–178.

121. Matsuda S, Shibasaki F, Takehana K, Mori H, Nishida E, Koyasu S. Two distinct action mechanisms of immunophilin-ligand complexes for the blockade of T-cell activation // EMBO Rep. - 2000. - Vol. 1, N 5. - Pp. 428-434.

122. Matsushita T, Hasegawa M, Hamaguchi Y, et al. Longitudinal analysis of serum cytokine concentrations in systemic sclerosis: association of interleukin 12 elevation with spontaneous regression of skin sclerosis // J Rheumatol - 2006. - Vol. 33, N 2 - Pp. 275–284.

123. Mattila L et al: Activation of tissue inhibitor of metalloproteinases-3 (TIMP-3) mRNA expression in scleroderma skin fibroblasts // J Invest Dermatol - 1998. - Vol. 110, N 4. - P. 416

124. Mauviel A, Heino J, Kahari VM, Hartmann DJ, Loyau G, Pujol JP, Vuorio E. Comparative effects of interleukin-1 and tumor necrosis factor-α on collagen production and corresponding procollagen mRNA levels in human dermal fibroblasts // J Invest Dermatol - 1991. - Vol. 96, N 2. - Pp. 243–249.

125. Meixner, A., Karreth, F., Kenner, L., and Wagner, E.F. JunD regulates lymphocyte proliferation and T helper cell cytokine expression // Embo J - 2004

- Vol. 23, N 6. - Pp. 1325-1335.

126. Meyrick Thomas RH, Ridley CM, Black MM. The association of lichen sclerosus et atrophicus and autoimmune-related disease in males // Br J Dermatol

- 1983. - Vol. 109, N 6. - Pp. 661–664.

127. Murota M, Fujimoto M, Matsushita T, Hamaguchi Y, Hasegawa M, Takehara K. Clinical association of serum interleukin-17 levels in systemic sclerosis: Is systemic sclerosis a Th17 disease? // J Dermatol Sci - 2008. - Vol. 50, N 3. - Pp. 240-242.

128. Needlemann BW, Wigley FM, Stair RW. Interleukin-1, interleukin-2, interleukin-4, interleukin-6, tumor necrosis factor α and interferonγ levels in sera

from patients with scleroderma // Arthritis Rheum - 1985. - Vol. 28, N 7 - Pp. 775-780.

129. Nickoloff B., Nestle F. Recent insite into the immunopathogenesis of psoriasis provide new therapeutic opportunities // J. Clin. Invest. - Vol. 113 , N 12. - Pp. 1664–1675.

130. O’Kane S, Ferguson MW. Transforming growth factor beta and wound healing // Int J Biochem Cell Biol. - 1997. - Vol. 29, N 1 - Pp. 63–78.

131. Ogawa F, Shimizu K, Muroi E, Hara T, Hasegawa M, Takehara K, et al. Serum levels of 8-isoprostane, a marker of oxidative stress, are elevated in patients with systemic sclerosis // Rheumatology - 2006. - Vol. 45, N 7. - Pp. 815-818.

132. Ogawa F, Shimuzu K, Hara T, Muroi E, Komura K, Takenaka M, et al.

Autoantibody against one of the antioxidant repair enzymes, methionine sulfoxide reductase A, in systemic sclerosis: association with pul- monary fibrosis and vascular damage // Arch Dermatol Res - 2010. - Vol. 302, N 1 - Pp. 27-35.

133. Oger E, Lernyer C, Dueymes M, Le Moigne E, Bressolette L, Escoffre M, et al.

Association between IgM anticardiolipin antibodies and deep venous thrombosis in patients without systemic lupus erythematosus // Lupus - 199. - Vol. 6, N 5 - Pp. 455–461.

134. Okano Y. Antinuclear antibody in systemic sclerosis (scleroderma) // Rheum Dis Clin North Am - 1996. -Vol. 22, N 4. - Pp. 709–735.

135. Ostlere LS, Harris D, Buckley C et al. Atypical systemic sclerosis following exposure to vinyl chloride monomer: a case report and review of the cutaneous aspects of vinyl chloride disease // Clin Exp Dermatol - 1992. -Vol. 17, N 3. -Pp. 208–210.

136. Palumbo K, Zerr P, Tomcik M, Vollath S, Dees C, Akhmetshina A, Avouac J, Yaniv M, Distler O, Schett G, Distler JH. The transcription factor JunD mediates transforming growth factor {beta}-induced fibroblast activation and fibrosis in systemic sclerosis // Ann Rheum Dis - 2011. - Vol. 70, N 7. - 1320-1326.

137. Peterson LS, Nelson AM, Su WP. Classification of morphoea (localized sclero- derma) // Mayo Clin Proc - 1995. - Vol. 70, N 11. - Pp. 1068–76.

138. Petrozzi JW, Wood MG, Tisa V. Palmar–plantar lichen sclerosus et atrophicus // Arch Dermatol - 1979. - Vol. 115, N 7. - P. 884.

139. Ponticos M, Harvey C, Ikeda T, Abraham D, Bou-Gharios G: JunB mediates enhancer/promoter activity of COL1A2 following TGF-beta induction // Nucleic acids research - 2009. - Vol. 37, N 16 - Pp. 5378-5389.

140. Powell J, Wojnarowska F, Winsey S et al. Lichen sclerosus premenarche: autoimmunity and immunogenetics // Br J Dermatol - 2000. - Vol. 142, N 3. - Pp. 481–484.

141. Rai R, Handa S, Gupta S et al. Bilateral en coup de sabre: a rare entity // Pediatr Dermatol - 2000. - Vol. 17, N 3. - Pp. 222–224Rauscher, F.J., 3rd, Sambucetti, L.C., Curran, T., Distel, R.J., and Spiegelman, B.M. Common DNA binding site for Fos protein complexes and transcription factor AP-1 // Cell - Vol. 52, N 3. - Pp. 471-480.

142. Reich, N., B. Maurer, A. Akhmetshina, P. Venalis, C. Dees, P. Zerr, K. Palumbo,

J. Zwerina, T. Nevskaya, S. Gay, O. Distler, G. Schett, JH Distler The transcription factor Fra-2 regulates the production of extracellular matrix in systemic sclerosis // Arthritis Rheum - 2010. - Vol. 62, N 1 - Pp. 280-90.

143. Renaudineau Y, Grunebaum E, Krause I, Praprotnik S, Revelen R, Youinou P, et al. Anti-endothelial cell antibodies (AECA) in systemic sclerosis- increased sensitivity using different endothelial cell substrates and association with other autoantibodies // Autoimmunity - 2001. - Vol. 33, N 3 - Pp. 171–179.

144. Rodnan GP, Lipinski E, Rabin BS, Reichlin M. Eosinophilia and serologic abnormalities in linear localized scleroderma // Arthritis Rheum -1977. - Vol.20 - P. 133.

145. Rowell NR, Tate GM. Failure to demonstrate the lupus anticoagulant in systemic sclerosis // Br J Dermatol - 1988. - Vol. 119, N 4 - P. 549.

146. Rowell NR. Acral pansclerotic morphoea with intractable pain / Burgdorf WHC, Katz SI // Clinical Dermatology: the CMO Case Collection/World Congress of Dermatology. Berlin: Scheltauer, 1987. - Pp. 178–80.

147. Roybal CN, Hunsaker LA, Barbash O, Vander Jagt DL, Abcouwer SF. The oxidative stressor arsenite activates vascular endothelial growth factor mRNA transcription by an ATF4-dependent mechanism // J Biol Chem. - 2005. - Vol. 280, N 21 - Pp. 20331–20339.

148. Roybal CN, Yang S, Sun CW, et al. Homocysteine increases the expression of vascular endothelial growth factor by a mechanism involving endoplasmic reticulum stress and transcription factor ATF4 // J Biol Chem. - 2004. - Vol.279, N 15. - Pp. 14844–14852.

149. Ruffatti A, Peserico A, Glorioso S et al. Anticentromere antibody in localized scleroderma // J Am Acad Dermatol - 1986. - Vol. 15, N 4 - Pp. 637–642.

150. Rustin MHA, Bull HA, Ziegler V et al. Silica exposure and silica associated systemic sclerosis // Br J Dermatol - 1989. - Vol. 121 (Suppl. 34) - Pp. 29.

151. Rutkowski DT, Kaufman RJ. All roads lead to ATF4 // Dev Cell - 2003. - Vol. 4, N 4. - Pp. 442– 444.

152. Saleh Z, Abbas O, Dahdah MJ, Kibbi AG, Zaynoun S, Ghosn S. Atrophoderma of Pasini and Pierini: a clinical and histopathological study // J Cutan Pathol. - 2008. - Vol. 35, N 12. - Pp. 1108-1114.

153. Sambo P, Baroni SS, Luchetti M, Paroncini P, Dusi S, Orlandini G, et al.

Oxidative stress in scleroderma: Maintenance of scleroderma fibroblast phenotype by the constitutive upregulation of reactive oxygen spe- cies generation through the NADPH oxidase complex pathway // Arthritis Rheum - 2001ю - Vol. 44, N 11. - Pp. 2653-2664.

154. Sambo P, Jannino L, Candela M, Salvi A, Donini M, Dusi S, et al. Monocytes of patients with sys- temic sclerosis (scleroderma) spontaneously release in vitro increased amounts of superoxide anion // J Invest Dermatol 1999 - Vol. 112, N 1.

- Pp. 78-84.

155.Sano, Y., Harada, J., Tashiro, S., Gotoh-Mandeville, R., Maekawa, T. and Ishii, S. ATF-2 is a common nuclear target of Smad and TAK1 pathways in transforming growth factor-β signaling // J. Biol. Chem. - 1999. - Vol. 274, N 3. - Pp. 8949-8957.

156. Sato S, Fujimoto M, Hasegawa M, Takehara K. Antiphospholipid antibody in localized scleroderma // Ann Rheum Dis - 2003. - Vol. 62, N 8. - Pp. 771–774.

157. Sato S, Fujimoto M, Ihn H, Kikuchi K, Takehara K. Clinical characteristics associated with antihistone antibodies in patients with localized scleroderma // J Am Acad Dermatol - 1994. - Vol. 31, N 4. - Pp. 567–571.

158. Sato S, Hasegawa M, Takehara K. Serum levels of interleukin-6 and interleukin- 10 correlate with total skin thickness score in patients with systemic sclerosis // J Dermatol Sci - 2001. - Vol. 27, N 2 - Pp. 140–146.

159. Sato S, Ihn H, Soma Y et al. Antihistone antibodies in patients with localized scleroderma // Arthritis Rheum - 1993. - Vol. 36, N 8 - Pp. 1137–1141.

160. Sawamura D, Yaguchi T, Hashimoto I et al. Coexistence of generalized morphea with histological changes in lichen sclerosus et atrophicus and lichen planus // J Dermatol - 1998. - Vol. 25, N 6 - Pp. 409–411.

161. Schreiber, S. L., and G. R. Crabtree. The mechanisms of action of cyclosporin A and FK506 // Immunol. Today - 1992. - Vol. 13, N 4. - Pp. 136–142.

162. Schuermann, M., Jooss, K., and Muller, R. fosB is a transforming gene encoding a transcriptional activator // Oncogene - 1991. - Vol. 6, N 4. - Pp. 567-576.

163. Seder RA, Marth T, Sieve MC, Strober W, Letterio JJ, Roberts AB, et al. Factors involved in the differen- tiation of TGFbeta-producing cells from naive CD4+ T cells: IL-4 and IFNgamma have opposite effects, while TGFbeta positively regulates its own production // J Immunol - 1998. - Vol. 160, N 12 - Pp. 5719-5728.

164. Serpier H, Gillery P, Salmon-Ehr V, Garnotel R, Georges N, Kalis B, et al.

Antagonistic effect of inter- feron-gamma and interleukin-4 on fibroblast cultures

// J Invest Dermatol - 1997. - Vol. 109, N 2. - Pp. 158-162.

165. Serup J, Serup L, Sjo O. Localized scleroderma ‘en coup de sabre’ with external eye muscle involvement at the same time // Clin Exp Dermatol - 1984. - Vol. 9, N 2. - Pp. 196–200.

166. Shaulian, E. and Karin, M. AP-1 in cell proliferation and survival // Oncogene - 2001. - Vol. 20, N 19. - Pp. 2390-2400.

167. Shimuzu K, Ogawa F, Akiyama Y, Muroi E, Yoshizaki A, Iwata Y, et al.

Increased serum levels of N(epsilon)-(hexanoyl)lysine, a new marker of oxidative stress, in systemic sclerosis // J Rheumatol - 2008. - Vol. 35, N 11. - Pp. 2214-2219.

168. Shi-Wen X, Holmes PD, Leask A, Bradham D, Beauchamp JR, Fonseca C, et al.

Autocrine overexpression of CTGF maintains fibrosis: RDA analysis of fibrosis genes in systemic sclerosis // Exp Cell Res - 2000. - Vol. 259, N 1. - Pp. 213– 224.

169. Shi-wen X, Kennedy L, Renzoni E, du Bois R, Denton C, Black C, et al.

Endothelin-1 is a downstream mediator of TGFβ in fibroblasts. Arthritis Rheum 2007 - Vol. 56, N 12. - Pp. 4189-4194.

170. Slack JL, Parker MI, Bornstein P. Transcriptional repression of the α1(I) collagen gene by ras is mediated in part by an intronic AP1 site // J Cell Biochem

- 1995. - Vol. 58, N 3. - Pp. 380–392.

171. Smeyne, R.J., Curran, T., and Morgan, J.I. Temporal and spatial expression of a fos-lacZ transgene in the developing nervous system // Brain Res Mol Brain Res

- 1992. - Vol. 16, N 1-2. - Pp. 158-162.

172. Soma Y, Fujimoto M. Frontoparietal scleroderma (en coup de sabre) following Blaschko's lines // J Am Acad Dermatol - 1998. - Vol. 38, N 2. - Pp.366-368.

173. Sonkoly E, Wei T, Janson PC, Saaf A, Lundeberg L, Tengvall-Linder M, Norstedt G, Alenius H, Homey B, Scheynius A et al: MicroRNAs: novel regulators involved in the pathogenesis of psoriasis? // PloS one - 2007. - Vol. 2, N 7. - e610.

174. Stanek G, Strle F. Lyme borreliosis // Lancet - 2003. - Vol. 362, N 9396. - Pp.

1639–1647.

175. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the clas- sification of systemic sclerosis // Arthritis Rheum - 1980. -Vol. 23, N 5. - Pp. 581–590.

176. Tajima S, Suzuki Y, Inazumi T. A case of atypical localized scleroderma presenting with pseudoainhum: treatment with tranilast, an anti-fibrotic agent // Acta Derm Venereol (Stockh) - 1996. - Vol. 76, N 2 - P. 162.

177. Takeda K, Hatamochi A, Ueki H, Nakata M, Oishi Y. Decreased collagenase expression in cultured systemic sclerosis fibroblasts // J Invest Dermatol - 1994.

- Vol. 103, N 3 - Pp. 359–363.

178. Takehara K, Sato S. Localized scleroderma is an autoimmune disorder // Rheumatology (Oxford). - 2005. - Vol. 44, N 3. - Pp. 274-279.

179. Tanjore, H., Blackwell, T. S. and Lawson, W. E. Emerging evidence for endoplasmic reticulum stress in the pathogenesis of idiopathic pulmonary fibrosis // Am. J. Physiol. Lung Cell. Mol. Physiol. - 2012. - Vol. 302, N 8. - Pp. 721–L729.

180. Tasker GL. Wojnarowska F. Lichen sclerosus // Clin Exp Dermatol - 2003. - Vol.

28, N 2 - Pp. 128–133.

181. ten Dijke P., Hill C.S. New insights into TGFβ– Smad signaling // Trends Biochem. Sci. - 2004. - Vol. 29, N 5 - Pp. 265–273.

182. Tollefson MM, Witman PM. En coup de sabre morphea and Parry-Romberg syndrome: a retrospective review of 54 patients // J Am Acad Dermatol. - 2007. - Vol. 56, N 2. - Pp. 257-263.

183. Trattner A, David M, Sandbank M. Bullous morphea: a distinct entity? // Am J Dermatopathol - 1994. - Vol. 16, N 414–417.

184. Tuffanelli DL, Winkelmann RK. Systemic scleroderma // Arch Dermatol - 1955. - Vol. 84 - Pp. 359–371.

185. Uitto J, Bauer EA, Eisen AZ: Scleroderma: increased biosynthesis of triple- helical type I and type III procollagens associated with unaltered expression of

collagenase by skin fibroblasts in culture. The Journal of clinical investigation 1979. - Vol. 64, N 4 - Pp. 921-930.

186. Varga J. Systemic sclerosis: an update // Bull NYU Hosp Jt Dis - 2008. - Vol. 66, N 3. - Pp. 198–202.

187. Veldhoen M, Stockinger B: TGFbeta1, a "Jack of all trades": the link with pro- inflammatory IL-17-producing T cells // Trends Immunol - 2006. - Vol. 27, N 8 - Pp. 358-361.

188. Weibel L, Harper JI. Linear morphoea follows Blaschko's lines // Br J Dermatol.

- 2008. - Vol. 159, N 1. - Pp.175-181.

189. Weill J, Dubois M, Lewin et al. Sclerodermie en bandes et atrophies tissulaires multiples // Bull Mem Soc Med Hop Paris - 1953. - Vol. 69 - Pp. 490–495.

190. Wilson PR. Porphyria cutanea tarda with cutaneous ‘scleroderma’ and calcification // Australas J Dermatol - 1989. - Vol. 30 - Pp. 93–96.

191. Wollina U, Buslau M, Heinig B, Petrov I, Unger E, Kyriopoulou E, et al.

Disabling pansclerotic morphea of childhood poses a high risk of chronic ulceration of the skin and squamous cell carcinoma // Int J Low Extrem Wounds

- 2007. - Vol. 6, N 4. - Pp. 291-298.

192. Wollina U, Buslau M, Weyers W. Squamous cell carcinoma in pansclerotic morphea of childhood // Pediatr Dermatol - 2002. - Vol. 19, N 2 - Pp. 151-154.

193. Yamamoto T. Autoimmune mechanisms of scleroderma and a role of oxidative stress // Self Nonself. - 2011. - Vol. 2, N 1 - Pp. 4–10

194. Yamamura Y, Hua X, Bergelson S, Lodish HF. Critical role of Smads and AP-1 complex in transforming growth factor-beta -dependent apoptosis // J Biol Chem

- 2000. - Vol. 275, N 46 - Pp. 36295-36302.

195. Yamane K, Ihn H, Kubo M, et al. Increased serum levels of soluble vascular cell adhesion molecule 1 and E-selectin in patients with localized scleroderma // J Am Acad Dermatol - 2000. - Vol. 42 - Pp. 64–9.

196. Yao Y., Richman L., Morehouse C. et al. Type I Interferon: Potential Therapeutic Target for Psoriasis? // PLoS One. - 2008. - V. 3, N. 7. - e2737, Pp.1-14.

197. Yao Z, Painter SL, Fanslow WC, Ulrich D, Macduff BM, Spriggs MK, Armitage RJ: Human IL-17: a novel cytokine derived from T cells // J Immunol - 1995. - Vol. 155, N 12. - Pp. 5483-5486.

198. Yin X, Wolford CC, Chang YS, McConoughey SJ, Ramsey SA, et al. ATF3, an adaptive-response gene, enhances TGF{beta} signaling and cancer-initiating cell features in breast cancer cells // J Cell Sci - Vol. 123, N 20. - Pp. 3558–3565

199. Yokoyama Y, Akimoto S, Ishikawa O. Disaccharide analysis of skin glycosaminoglycans in atrophoderma of Pasini and Pierini // Clin Exp Dermatol - 2000. - Vol. 25, N 5. - Pp. 436-40.

200. Zavadil, J., E.P. Bottinger. TGF-beta and epithelial-to-mesenchymal transitions //

Oncogene - 2005. -Vol. 24 - Pp. 5764–5774.

201. Zenz R, Eferl R, Kenner L, Florin L, Hummerich L, Mehic D, et al. Psoriasis- like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins // Nature - 2005. - Vol. 437 - Pp. 369–375.

202. Zhang, Y., Feng, X.-H. and Derynck, R. Smad3 and Smad4 cooperate with c-Jun/ c-Fos to mediate TGF-β-induced transcription // Nature - 1998 - Vol. 394 - Pp. 909-913.

203. Zulian F, Martini G. Preliminary classification criteria for juvenile systemic scle- rosis. In: Zulian F, Ruperto N, eds. Proceedings of the II Workshop on Nomenclature and Diagnostic Criteria for Juvenile Scleroderma Syndromes // Padua: Associazione II Volo, 2005. Pp 5–16.

204. Zulian F. Systemic manifestations in localized scleroderma // Curr Rheumatol Rep. Dec - 2004. - Vol. 6. N 6. - Pp. 417-424.